Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world’s most populous nation, a senior executive said on Thursday. “I do think there is promise for products like that (orforpligron) in India, if it does get approved,” Winselow Tucker, Lilly India’s president said at…
Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs. The deal would help Roche grow in a field related to the booming weight-loss market, where the company has recently made…
Novo Nordisk’s Wegovy, Fiasp, Ryzodeg Injectables Stolen During Transit, DCGI Issues Alert We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
From Breakthrough to Backlash: Novo Nordisk’s Ozempic Faces USD 2 Billion Lawsuit We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
US drugmaker Eli Lilly‘s weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country’s fastest-growing prescription brands ever by value. The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If…
Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a “good” share of the market, Krishnakumar Vaidyanathan, executive director and chief operating…
Pharma major Eli Lilly today said that it’s weight loss drug Mounjaro has helped in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease. According to the results of the trial which included over 13,000 patients across 30 countries, including India, 16 % reduction in all-cause mortality was seen, 8% lower risk…